Yüksel Ürün: MFS continues to be a reliable predictor for overall survival

Yüksel Ürün, Medical Oncologist at Ankara University, shared on X:

“With better access to docetaxel and other treatments for advanced prostate cancer, MFS continues to be a reliable predictor for overall survival. This reinforces MFS’s role as the main outcome for current adjuvant trials in localized prostate cancer, impacting future trial designs.”

For more details click here.
Source: Yüksel Ürün/X